

Index

Tables are referred to in **bold**, figures in *italics*

- 1000 Genomes Project, 52, 53, 56–58, **59**, 59
- 23andMe, Inc., 10
 - accuracy issues, 12
 - disease testing, 12
 - paternity testing, 110
 - privacy concerns, 15, 90
 - reference panels, 53
 - retail DNA test, 12
 - twins, 121–124
- accuracy issues, 7, 118, 126–127
 - 23andMe, Inc., 12
 - allele frequencies in populations, 126–127
 - ancestry companies comparisons, 118–119, 127–128
 - DNA analysis, 122–123, 123
 - DNA markers and ancestry regions, 120–121
 - self-declared vs. genomic ancestry, 124–125
 - twins, 121–124
- adoption tracing, 110–111, 117
- advertising claims, 92–93
- African Americans, 44, 104
- African ancestry, 124
- AIMs *see* ancestry informative markers
- ALFRED (allele frequency database), 50, 52, **59**, 59
- allele frequencies in populations, 24–25, 31
 - accuracy issues, 126–127
 - ancestry inference methods, 50
 - ancestry informative markers, 48–49
 - basis for DNA testing, 25
 - biogeographical ancestry, 26
 - gene variants, 26–28, 29
 - measurement, 67, **68**
 - principal component analysis (PCA), 35
 - scientific basis, 35–36, 103–105, 122
 - statistics, 66–72, **67**, **68**, **70**
- alleles, unique, 26, 44; *see also* ancestry informative markers
- American Society of Human Genetics (ASHG), 16, 124–125
- amplification, SNPs, 74
- ancestry, genealogy vs. genetics, 4–6
- Ancestry Composition algorithm, 23andMe, Inc., 53
- ancestry inference, 29, 72

- flow chart, 77
- reliability, 30, 50, 127
- requirements, 52
- scientific validation, 33–34, 47
- stages, 36–40
- ancestry informative markers (AIMs), 6, 27–28, 29–33, 41
- accuracy issues, 34
- autosomal ancestry tests, 46–49
- biogeographical accuracy, 119
- DNA analysis, 76
- family discoveries, 106
- forensics, 43–44
- mitochondrial DNA markers, 44–45
- optical fibers as DNA probes, 77, 78
- stages for inferring ancestry, 39–40
- Y chromosome DNA, 45–46
- AncestryDNA (business), 9–10, 13–14
- autosomal SNP ancestry markers, 47
- DNA sampling, 73
- privacy concerns, 15
- reference panels, 52, 54–55, 56–58, **57–58**
- stages for inferring ancestry, 37–40
- twins, 121–124
- white paper, 37
- ancestry tests see autosomal ancestry tests
- anonymity, sperm donors, 113
- anthropology
 - migrations, 51
 - mitochondrial DNA, 45
 - racial classification, 102
- anti-discrimination legislation, 101–102
- ASHG see American Society of Human Genetics
- Asian ancestry, 124
- Asian reference panels, 55
- Australopithecus afarensis*, 20, 21
- autosomal ancestry tests, 8–9, 10, 14
 - Frudakis–Shriver Patent Application, 28, 31
 - paternity testing, 106
- autosomal SNP ancestry markers, 46–49, 60
- baby swapping, 112–113
- bio-chips see DNA probes
- biogeographical ancestry (BGA), 17, 34, 54–55, 60, 126
- accuracy issues, 120–121
- allele frequencies in populations, 35–36
- ancestry informative markers, 30–31, 41, 48–49
- autosomal SNP ancestry markers, 47–48
- forensics, 86
- individual trait, 29
- reference panels, 51
- scientific basis, 16
- biological parents, 1
- blood typing, **107**, 107–108
 - human leukocyte antigens, 108
- breast cancer, 11, 12
- business perspectives, 3, 6, 8
 - ancestry services, 8–10
 - consumer motivation, 14–16
 - genetic tests, types, 13–14
 - health market, 11–13
- cell lines, ownership, 88–90
- centimorgans (cM), 39, 84
- Combined DNA Index System (CODIS), 1, 42, 80, 81
- commercial perspectives see business perspectives
- comparisons, ancestry companies, 118–119, 121
- complementary base pairing, 74
- confidence levels, test results, 119
- consent, use of genetic data, 88–89, 90, 94–95, 96

148 INDEX

- consistency concerns, 15–16
 consumer motivation, 14–16
 consumer rights, DNA, 89–90
 consumer testing kits, 8
 copy number variants, 63
 counseling, genetic, 95
 cousins, DNA matching, 94
 crime investigations *see* forensic applications
 cultural values, ancestry, 4–6, 98, 100
- data
 ownership, 88–90
 privacy concerns, 90–92
- deletion–insertion polymorphisms (DIPs), 29
- descent, identity by, 82–86
- digital ancestry services, 9–10
- direct-to-consumer (DTC) DNA tests, 8, 11, 14, 93
 accuracy issues, 121
 advertising claims, 92–93
 family discoveries, 106
- disease-bearing mutations, 50
- disease risk diagnosis, 6
- disease testing, 12
- diversity quotas, 15
- DNA (deoxyribonucleic acid) analysis, 74–75
 accuracy issues, 122–123, 123
 forensic applications, 79–80
 racial classification, 102–103
- DNA Diagnostic Center (DDC), 110
- DNA fingerprinting, 1
- DNA Identification Act, 42
- DNA markers *see* genetic markers
- DNAPrint Genomics (business), 8–9, 28
- DNA probes, 30, 30, 32, 74, 75, 76–77;
see also microarrays
- DNA sampling, 73
- DNA variants/variations *see* genetic variants
- drift, genetic, 29
- drug responses, genomes, 50
- DTC *see* direct-to-consumer DNA tests
- economic motives, 15
- electrophoresis, 22, 23
 restriction fragment length polymorphisms, 108
 unique alleles, 44
- Estonian Biocentre, 59
- ethical issues, 7, 88
 advertising claims, 92–93
 forensic and privacy concerns, 93–98
 ownership, 88–90
 personal identity, 98–102
 privacy concerns, 90–92
 racial classification, 102–105
 sperm donation, 115
- ethnicity
 AncestryDNA white paper, 37, 39–40, 54–55
 biogeographical ancestry, 16
 estimates, 57–58, 73
 family discoveries, 112–113, 115–117
- European ancestry, 120, 124
- familial genealogy *see* genealogy
- familial searches, 80–81
- family discoveries, 7, 106, 127
 DNA and paternity claims, 110
 ethnicity, 112–113, 115–117
 hidden secrets, 1, 110–111
 sperm donation, 113–115
- Family Tree DNA (business), 8, 9, 37, 59
- family trees
 AncestryDNA, 56–58
 family discoveries, 110–111
 forensic applications, 82, 85, 94
 genealogy, 2, 4–6

- FBI, use of gene sequencing, 1, 80
- female-specific perspectives, 45
- fertility clinics, 116
- fingerprinting, DNA, 1
- fixation index (F_{ST}), 66–72
- folate, 18
- Food and Drug Administration (FDA), 12
- forensic applications, 1, 7, 29, 79
 - ancestry informative markers, 43
 - DNA analysis, 79–80
 - genetic markers, 41
- Golden State Killer, 81–83
- Grim Sleeper, 80–81
- identity by descent, 83–86
- phenotyping, 86–87
- privacy concerns, 91–92, 93–98
- reference panels, 50–51
- Frudakis, Tony N., 28, 46–47
- Frudakis–Shriver Patent Application, 28, 31
- future trends, 126–128
- GEDMatch, genealogy website, 82–83, 85, 97
- Gene by Gene Ltd., 8, 9
- gene-chips *see* DNA probes
- genealogy, 2, 51
 - forensic applications, 82
 - vs.* genetics, 4–6
 - reference panels, 51
 - use of genome, 3–4
 - whole-genome scans, 13
- genetic ancestry *vs.* self-declared, 124, **125**
- genetic counseling, 95
- genetic data, privacy concerns, 90–92
- genetic determinism theory, 104
- genetic diversity, 6, 17, 22–25
 - distance from East Africa, 22
 - Homo sapiens* evolution, 20–21
 - isolated populations, 18–20, 22
 - reference panels, 51
 - within/between* populations, 22–24, 26, 28
- genetic drift, 29
- Genetic Information Non-Discrimination Act, 90, 97
- genetic markers, 6
 - autosomal ancestry tests, 46–49
 - biogeographical ancestry, 4, 16, 18–19, 29, 70, 124
- forensic applications, 42–43
- genealogy, 2
- medical uses, 50
- paternity testing, 108–110
- population-specific variants, 63–66
 - within/between* populations, 23, 26
- genetic tests, regulation, 13; *see also*
 - autosomal ancestry tests
- genetic variants, 3, 60–63, **61–62**, 65; *see also* polymorphisms
- allele frequencies, 26–28
- database, 49
- South American Indians, 44
- Geographic Project, 9
- genome sequencing, 2–3
- genomic ancestry tests *see* autosomal ancestry tests
- genomic information, ownership, 88–90
- geographical origins *see* biogeographical ancestry
- Golden State Killer, 81–83
- Greenspan, Bennett, 9
- Grim Sleeper, serial killer, 80–81
- haplogroups, 45
- haplotypes, 27
 - AncestryDNA, 39
 - DNA analysis, 76
- HapMap SNP database, 119
- health market, 11–13
- Hela cell line, 88–89

150 INDEX

- hemoglobin allele (Hb*s), 33
heterozygosity, 67, 68, **69**
HGDP see Human Genome Diversity Project
Hispanic ancestry, 124
historical figures, connections, 100
historical genealogy, 2
Homo erectus, 20
Homo habilis, 20
Homo sapiens evolution, 20–21
Homo sapiens sapiens, 20, 22
homozygosity, 67, 68, **69**
human genetic diversity see genetic diversity
Human Genome Diversity Cell Line Panel, 47–48
Human Genome Diversity Project (HGDP), 47, 52, 56–58, 59
human genome project, 22
human leukocyte antigens, paternity testing, 108
hybridization, 30, 74
hypervariable microsatellites, 60
- identity by descent, 82–86
inbreeding, 17
indigenous populations, 36
individuals' DNA, 60, 72
inferring ancestry see ancestry inference
inherited biochemical variants, 44
International HapMap Project, 52, 59
interpretation, genetic data, 120–121
isolated populations, human genetic diversity, 18–20, 22
- Lewontin, Richard, 22–25
linkage disequilibrium, 83
- malaria, 33
markers, DNA see genetic markers
maternal lineages, 13–14, 44
- medical aspects, 11–13
medical genome sequencing, 2
melanin, 18
microarrays, 6–7, 30, 30, 32, 72, 73; see also DNA probes
DNA analysis, 74–75
optical fibers, 75, 76–77
microsatellites see autosomal SNP
ancestry markers
migrations, 22, 35, 36, 51, 56
minority business enterprise (MBE), 101–102
minority status, 102
mitochondrial DNA (mtDNA), 13–14, 32, 44–45, 60
Mo cell line, 89
monocentric theory, human evolution, 20
multiregional theory, human evolution, 20
mutations, 50
disease-bearing, 50
frequency differences within populations, 26
My Heritage, Inc., 121–124
- National Human Genome Research Institute, 41, 52
Native American heritage, 98–99
Nebula Genomics, Inc., 13
- Office of Minority and Women's Business Enterprises (OMWBE), 101–102
oligonucleotide probes, 74, 76–77
1000 Genomes Project, 52, 53, 56–58, **59**, 59
open-access platforms, 13
optical fibers as DNA probes, 75, 76–77
Out of Africa hypothesis, 20
ownership, cells, and genomic information, 88–90

- Parabon Nanolabs, 85–86
- Parkinson's disease, 12
- patents, 27, 28
- paternal lineages, 13–14
- paternity, false, 94–95
- paternity testing, 117
- blood typing, 108
 - DNA, 106, 108–110
- PCA *see* principal component analysis (PCA)
- PCR *see* polymerase chain reaction
- personal identity, 98–102
- pharmaceutical industry, 15
- pharmaco-genetically relevant polymorphisms, 50
- phenotypes/phenotyping, 22, 81, 86–87
- autosomal SNP ancestry markers, 46–47
 - forensics, 43
 - properties, 29
- Plasmodium falciparum*, 33
- political motives, 15
- polycentric theory, human evolution, 20
- polymerase chain reaction (PCR), 31
- amplification, 74
 - paternity testing, 108–110
- polymorphisms, 3, 41; *see also* single nucleotide polymorphisms
- population frequencies of variants, 66–72, 81, 127–128
- single nucleotide polymorphisms, 35–36, **37**, 127
- population genetics, 25, 28, 51, 122
- population reference panels *see* reference panels
- population-specific alleles (PSAs), 32–33, 63–66; *see also* ancestry informative markers
- population structure, 25, 27, 29
- allele frequencies, 35
 - cattle breeds, 66
 - reference panels, 34
- principal component analysis (PCA), 25, 35, 120
- privacy concerns, 15
- forensics, 93–98
 - genetic data, 90–92
 - medical data, 12
- probes, DNA, 30, 30, 32, 74, 75, 76–77; *see also* microarrays
- proprietary reference panels, 51–55, 122, 126
- 23andMe, Inc., 53
 - AncestryDNA, 52, 54–55
 - non-standardized, 53–54
 - public- and private-sector funded, 52
- prostate cancer, 12
- PSAs *see* population-specific alleles
- racial classification, 94–95
- discreditation, 102
 - DNA analysis, 102–103
 - genetic identity, 103–105
 - government use, 102
 - social construction, 103
- racial considerations, 24
- racial identities
- reinforcement, 102, 103–104
 - social construction, 103
- recreational genomics, 8
- reference panels, 6, 34–35; *see also* proprietary reference panels
- allele frequencies in populations, 36
 - ancestry informative markers, 48–49
 - AncestryDNA, 39
 - Asian, 55
 - donor DNA comparisons, 60–72
 - Family Tree DNA, 37
 - individual comparisons, 6
 - inferring ancestry, 36, 50–51
 - uncertainties, 128
 - validation, 55–59

152 INDEX

- regional ancestry *see* biogeographical ancestry
- reinforcement, racial identities, 102, 103–104
- restriction fragment length polymorphisms (RFLP), 108
- scientific perspectives, 6, 26
allele frequencies, 26–28, 35–36
ancestry markers, 29–33
gene variants, 26–28
inferring ancestry, 33–34, 36–40
patents, 28
reference panels, 34–35
- secondary market, ancestry DNA, 88
- self-declared vs. genetic ancestry, 124, **125**
- self-uncertainty, 14–15
- selling DNA, 88
- sequencing genomes, 2–3
- short indels, 60–63, **61–62**
- short tandem repeats (STRs), 60–63, **61–62**
ancestry inference, 45–46, 60
forensic applications, 1, 42–43, 79
Y chromosome DNA, 45–46
- Shriver, Mark D., 28, 29, 63
- sickle cell anemia, 33
- single nucleotide polymorphisms (SNPs), 60–63, **61–62**
amplification, 74
ancestry markers, 29, 34
biogeographical accuracy, 119
comparing DNA, 13
human genome, 27–28
inferring ancestry, 32–33, 34
paternity testing, 110
population frequencies, 35–36, **37**, 127
- skin color, 18, 23, 24
- slavery, 100–101
- SNPs *see* single nucleotide polymorphisms
- social construction, race as, 103
- sperm donation, 113–115, 116
- STRs *see* short tandem repeats
- structural copy number variants, 60–63
- sub-Saharan Africa, 27
- testing accuracy *see* accuracy issues
- testing kits, consumer, 8
- 1000 Genomes Project, 52, 53, 56–58, **59**, 59
- tribal communities, 100
- twins, 121–124
- 23andMe, Inc., 10
accuracy issues, 12
disease testing, 12
paternity testing, 110
privacy concerns, 15, 90
reference panels, 53
retail DNA test, 12
twins, 121–124
- two-sided market strategy, 11
- uncertainty–identity theory, 14–15
- unique alleles, 26, 44; *see also* ancestry informative markers
- validity concerns
ancestry inference, 33–34, 47
DNA tests, 15–16
reference panels, 55–59
- values, cultural, 4–6, 98, 100
- Verogen, Inc., 84
- Viking heritage, 99–100
- vitamin D, 18
- Walt, David, 75
- whole-genome scans, 13
- Y chromosome DNA, 13–14, 32, 45–46, 60